TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas - Wikidata - awgldk - TriplyDB

TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas

TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas

http://www.wikidata.org/entity/Q34313648

about

Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical Implications Transcription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) Gene Genetic Testing in Differentiated Thyroid Carcinoma: Indications and Clinical Implications TERT promoter mutations in thyroid cancer Mutation Profile of Well-Differentiated Thyroid Cancer in Asians Time to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinoma Current status and future perspectives in differentiated thyroid cancer Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy.Telomerase Activation in Hematological Malignancies Integrated genomic characterization of papillary thyroid carcinoma 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer Hobnail variant of papillary thyroid carcinoma: molecular profiling and comparison to classical papillary thyroid carcinoma, poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma Ultrasound is helpful to differentiate Bethesda class III thyroid nodules: A PRISMA-compliant systematic review and meta-analysis.Molecular Signature of Indeterminate Thyroid Lesions: Current Methods to Improve Fine Needle Aspiration Cytology (FNAC) Diagnosis.A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinoma Molecular approaches to thyroid cancer diagnosis.Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer.Characterization of thyroid cancer cell lines in murine orthotopic and intracardiac metastasis models.Clinical Characteristics and Prognostic Significance of TERT Promoter Mutations in Cancer: A Cohort Study and a Meta-Analysis.BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients.Association of telomerase reverse transcriptase promoter mutations with clinicopathological features and prognosis of thyroid cancer: a meta-analysis.BRAF(V600E) mutation is highly prevalent in thyroid carcinomas in the young population in Fukushima: a different oncogenic profile from Chernobyl Association of TERT Promoter Mutation, But Not BRAF Mutation, With Increased Mortality in PTC.Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Carcinomas.Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.Low frequency of TERT promoter mutations in gastrointestinal stromal tumors (GISTs).Low Prevalence of Somatic TERT Promoter Mutations in Classic Papillary Thyroid Carcinoma The TERT promoter SNP rs2853669 decreases E2F1 transcription factor binding and increases mortality and recurrence risks in liver cancer.TERT promoter mutations in pancreatic endocrine tumours are rare and mainly found in tumours from patients with hereditary syndromes TERT Promoter Mutations and Tumor Persistence/Recurrence in Papillary Thyroid Cancer.BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients TERT promoter Mutation and Its Association with Clinicopathological Features and Prognosis of Papillary Thyroid Cancer: A Meta-analysis Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients.Genomic Profiling of Thyroid Nodules: Current Role for ThyroSeq Next-Generation Sequencing on Clinical Decision-Making Clinicopathological characteristics of TERT promoter mutation and telomere length in hepatocellular carcinoma Molecular markers for thyroid cancer diagnosis, prognosis, and targeted therapy.TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas.Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients.

P2860

Q26738705-777644D6-DBF8-4AE3-BFF1-2CFFE58926F0 Q26739925-834A38C9-C079-410D-B81D-E1606664C525 Q26765085-C167B0B6-2488-4A60-B91A-ACAF95A43060 Q26770808-632759C2-C926-4E5E-8806-F8412C9ED1F7 Q26782322-EEECE2D2-125A-4F71-B411-0D7A0E99791C Q26853261-E8D8FAF8-7548-4D96-AE8C-953F587E9916 Q27024484-E952A6F2-C2E3-44D3-89C1-435B365315DB Q27027491-C6094126-58E2-420D-B1E3-7485999DE761 Q27853057-7C8DC4D3-5C34-4A16-95D2-4FC75A651E2D Q28068238-0BB23E4E-4BB9-4AD7-8311-0C86A759916A Q28251986-A7AAACC8-46CF-420E-9CEC-2055F794940C Q30367068-CBF9451E-2FD0-472F-9373-ABCD0DF42A86 Q33591794-5D68CBC6-45F6-4250-B204-3F55EBC2DC2C Q33606108-9D4A90C5-6D52-4470-8289-BFCEA4A245E7 Q33624558-9DCBC8C0-1275-41E7-AF0A-7849E70F07FC Q33656624-BE9C2312-9388-4E86-8989-65387FBF4B95 Q34160828-649A51DD-911A-48A1-888F-F869532CAF72 Q35441872-2C27F7F5-FFB5-482A-9EA5-B18574E8E60F Q35554680-C0E7E0C9-3921-4CB7-8EA5-3D69C31E1005 Q35901458-F2A3536F-4D40-4C3E-8192-1EDB133EB79B Q35985808-225CED5B-D8CF-4D88-8532-B161796AF7E1 Q36221232-6061632B-E2E9-4A0F-B5C8-BEB63788DCA2 Q36301491-78E0B720-CEE0-46E6-A485-3D2143C68656 Q36339926-5DC5F750-E6B1-4ACB-A484-96CB05B36851 Q36452225-7DDC6366-A341-42D9-8592-33FF12F7034D Q36560914-977A8123-18B8-488B-AD65-44DAF442C3A8 Q36618604-80397C6F-B916-4E22-9508-EEC73556BF26 Q36695151-A9FA2ABA-D03E-4498-B5BB-45E9CB8D579A Q36716977-575F518A-D7FF-4B60-9745-38DCD4A3D210 Q36729504-8F4E80B6-9609-4326-8495-919AA55DD4AE Q37093384-545EB0D0-16CF-44F2-BAA7-5EBB2E60ED80 Q37097535-78A7D6BD-9E91-486B-A21C-C4F68F2E5958 Q37109755-D6D55AB8-2BC1-4A60-9721-EDB3CAC03D1D Q37408393-06C0AED2-CF3E-45D7-8757-67AFE010688B Q37605033-954E1EC0-6AA6-4399-A704-E96C9ACDC223 Q37616591-751A7D1D-7638-42CF-8BFE-F9C42AB80EE7 Q37626548-4676DCD4-1C31-4AD9-93FA-14B2AA22B4B4 Q38243095-24248A6C-2A1E-48F1-821E-A26242578D94 Q38383121-9FB22FA8-BE2F-41B6-81A1-F545D0B180D0 Q38416278-76F92AE3-9D7F-4384-8B8C-EA569B7C4E8B

P2860

TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas

http://www.wikidata.org/entity/Q34313648

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

TERT promoter mutations are a ...... ferentiated thyroid carcinomas

@ast

TERT promoter mutations are a ...... ferentiated thyroid carcinomas

@en

TERT promoter mutations are a ...... ferentiated thyroid carcinomas

@nl

type

label

TERT promoter mutations are a ...... ferentiated thyroid carcinomas

@ast

TERT promoter mutations are a ...... ferentiated thyroid carcinomas

@en

TERT promoter mutations are a ...... ferentiated thyroid carcinomas

@nl

prefLabel

TERT promoter mutations are a ...... ferentiated thyroid carcinomas

@ast

TERT promoter mutations are a ...... ferentiated thyroid carcinomas

@en

TERT promoter mutations are a ...... ferentiated thyroid carcinomas

@nl

P1433

Q34313648-B5259CDB-F33D-4A23-BD67-132AC042BB88

P1476

Q34313648-A5EDB352-E3CD-4AEF-9E20-16E141963F57

P2093

Q34313648-0D14628C-2B0D-4574-9327-02F438BAE836

Q34313648-1A403D5C-69EC-486A-AB48-6A95FCA141C3

Q34313648-399824CA-2E8D-4C04-A04D-E984BD411354

Q34313648-3B09D13F-7F1C-4C7F-8B64-D2937AF687BE

Q34313648-60BF7909-7205-40F4-98D2-428FA27D1C2B

Q34313648-AE0B25E1-956D-4782-BA22-AEF92C4F33E2

Q34313648-EED5B8D0-C316-48CF-BE25-902958DA9BC8

Q34313648-F2035E50-08C1-4673-81D1-252D0B407C05

Q34313648-F2334E5A-84E4-4D5E-BBDB-4F4E7AFFAD06

P2860

Q34313648-000538E3-B6E0-4881-BF33-D5F1655C9DDF

Q34313648-00464675-D6D0-423B-B88C-B54BA42A3C57

Q34313648-21BFFD84-6B05-41F2-AE0C-20ACC8BC29C8

Q34313648-247399ED-2DCC-4925-809D-70A473E8A9D4

Q34313648-32B31871-8AEB-4CD3-B199-D31510C4D2E1

Q34313648-430F31F0-7A40-4E77-9E0F-06981F468B6C

Q34313648-4D8CB098-7757-4774-9061-E0BFE274B9C0

Q34313648-4FADB730-2977-4DB6-A083-B041E1AFC778

Q34313648-65C7AD70-1792-49B0-91DA-A69CF2CD1642

Q34313648-6DF0D30F-CCBC-4D41-84DB-7525041C9311

P304

Q34313648-6A695FF2-F243-47C8-8942-1D18DB787F0F

P31

Q34313648-ADDD3ACE-0C47-45AB-8D16-AEFE1FF5B338

P356

Q34313648-6F64D8B0-8485-43CE-8C06-AAA961911E43

P407

Q34313648-544D7EE3-85F5-4880-BA15-96AEDB3B861F

P433

Q34313648-C936E8E4-6861-4551-87BE-386CA40FD3D2

P478

Q34313648-7A314E6E-85D4-4B06-ADB3-A46CF8525B72

P50

Q34313648-12D6AB0A-3858-4653-8711-D4F90F4F1680

Q34313648-22E565A3-736E-4AEC-9DAD-BD9D90781B4B

Q34313648-846E79E8-5CBE-49D4-930A-18D1D1D311C6

Q34313648-8A401E7E-4DA4-489C-8A10-668C5CC9E64A

Q34313648-99280D80-F9E6-464D-B3F9-6C9CA6056F5F

Q34313648-A0F6FAC7-FFF8-47A7-BCF1-D57FBAB30D66

Q34313648-A30D8180-8926-4E36-BB84-BB8908FF84C7

Q34313648-A950DBC1-EB06-417E-B33B-2FA967562530

Q34313648-B84A9C3E-701B-4D96-9C1B-E6FB1105A2A3

Q34313648-BDE4CFC2-6F5F-4F14-82B1-D573995E65D3

P577

Q34313648-DFC4B1CA-63E8-4C46-908F-1EFD5BFE7AC9

P5875

Q34313648-A14B2FBC-024B-4AC3-8E81-4C508B3C3110

P698

Q34313648-FB7C4439-AA0C-4930-AC1D-ADAAE364E323

P932

Q34313648-E3F16957-D55C-429C-A469-8D45B4744AEA

P356

P1433

The Journal of Clinical Endocrinology and Metabolism

P1476

TERT promoter mutations are a ...... ferentiated thyroid carcinomas

@en

P2093

Ana Almeida

http://www.w3.org/2001/XMLSchema#string

Catarina Tavares

http://www.w3.org/2001/XMLSchema#string

Cláudia Lobo

http://www.w3.org/2001/XMLSchema#string

Francisco Carrilho

http://www.w3.org/2001/XMLSchema#string

José Manuel Cameselle-Teijeiro

http://www.w3.org/2001/XMLSchema#string

Manuela Carvalheiro

http://www.w3.org/2001/XMLSchema#string

Maria João Martins

http://www.w3.org/2001/XMLSchema#string

Teresina Amaro

http://www.w3.org/2001/XMLSchema#string

Valdemar Máximo

http://www.w3.org/2001/XMLSchema#string

P2860

The Hallmarks of Cancer

Telomere elongation in immortal human cells without detectable telomerase activity

Highly prevalent TERT promoter mutations in aggressive thyroid cancers.

Specific association of human telomerase activity with immortal cells and cancer

The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations

Highly recurrent TERT promoter mutations in human melanoma

A survey of telomerase activity in human cancer

TERT promoter mutations in familial and sporadic melanoma

Accessories to the crime: functions of cells recruited to the tumor microenvironment

A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]

P304

E754-65

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1210/JC.2013-3734

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P50

Manuel Sobrinho-Simões

Branca M. Cavaco

Valeriano Leite

Ricardo Celestino

P577

2014-01-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259984125

http://www.w3.org/2001/XMLSchema#string

P698

24476079

http://www.w3.org/2001/XMLSchema#string

P932

4191548

http://www.w3.org/2001/XMLSchema#string